English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/160231
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorGrijalvo, Santiagoes_ES
dc.contributor.authorAdagia, Adelees_ES
dc.contributor.authorJorge, Andreia F.es_ES
dc.contributor.authorEritja Casadellà, Ramónes_ES
dc.identifier.citationGenes 9(2): 74 (2018)es_ES
dc.description.abstractOligonucleotide-based therapy has become an alternative to classical approaches in the search of novel therapeutics involving gene-related diseases. Several mechanisms have been described in which demonstrate the pivotal role of oligonucleotide for modulating gene expression. Antisense oligonucleotides (ASOs) and more recently siRNAs and miRNAs have made important contributions either in reducing aberrant protein levels by sequence-specific targeting messenger RNAs (mRNAs) or restoring the anomalous levels of non-coding RNAs (ncRNAs) that are involved in a good number of diseases including cancer. In addition to formulation approaches which have contributed to accelerate the presence of ASOs, siRNAs and miRNAs in clinical trials; the covalent linkage between non-viral vectors and nucleic acids has also added value and opened new perspectives to the development of promising nucleic acid-based therapeutics. This review article is mainly focused on the strategies carried out for covalently modifying siRNA and miRNA molecules. Examples involving cell-penetrating peptides (CPPs), carbohydrates, polymers, lipids and aptamers are discussed for the synthesis of siRNA conjugates whereas in the case of miRNA-based drugs, this review article makes special emphasis in using antagomiRs, locked nucleic acids (LNAs), peptide nucleic acids (PNAs) as well as nanoparticles. The biomedical applications of siRNA and miRNA conjugates are also discussed.es_ES
dc.description.sponsorshipThis work was supported by the Ministerio de Economía, Industria y Competitividad (CTQ2014-52588-R, CTQ2017-84415-R, RTC-2014-2038-1), Generalitat de Catalunya (2014/SGR/624) and the Instituto de Salud Carlos III (ISCIII) (CB06_01_0019). CIBER-BBN is an initiative funded by the VI National R + D + i Plan 2008–2011, Iniciativa Ingenio 2010, Consolider Program, CIBER actions and financed by ISCIII with assistance from the European Regional Development Fund. A.F.J. acknowledges Fundaçao para a Ciência e Tecnologia (FCT), Portugal, for financial support regarding post-doctoral grant SFRH/BDP/104544/2014. CQC issupported by FCT through the project No. 007630UID/QUI/00313/2013, co-funded by COMPETE2020-UE.es_ES
dc.publisherMultidisciplinary Digital Publishing Institutees_ES
dc.relation.isversionofPublisher's versiones_ES
dc.subjectCovalent approaches_ES
dc.subjectGene deliveryes_ES
dc.subjectGen therapyes_ES
dc.subjectNon-coding RNAes_ES
dc.subjectmiRNA technologyes_ES
dc.subjectRNA interferencees_ES
dc.subjectNucleic acid conjugateses_ES
dc.titleCovalent Strategies for Targeting Messenger and Non-Coding RNAs: An Updated Review on siRNA, miRNA and antimiR Conjugateses_ES
dc.description.peerreviewedPeer reviewedes_ES
dc.contributor.funderMinisterio de Economía, Industria y Competitividad (España)-
dc.contributor.funderGeneralitat de Catalunya-
dc.contributor.funderInstituto de Salud Carlos III-
oprm.item.hasRevisionno ko 0 false*
Appears in Collections:(IQAC) Artículos
Files in This Item:
File Description SizeFormat 
Covalent Strategies for Targeting Messenger and.pdf3,94 MBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.